Last reviewed · How we verify
NCT03179553: HeartBeat
Heart Beat Variability in Neonatal Encephalopathy
trial in Neonatal Encephalopathy in 210 participants. Status unknown.
28 August 2023
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 210 |
| Start date | 15 August 2017 |
| Primary completion | 28 August 2023 |
| Estimated completion | 28 November 2025 |
| Sites | 5 locations across United Kingdom |
Conditions studied
- Neonatal Encephalopathy — all drugs for Neonatal Encephalopathy →
- Asphyxia Neonatorum — all drugs for Asphyxia Neonatorum →
- Hypoxic-Ischemic Encephalopathy — all drugs for Hypoxic-Ischemic Encephalopathy →
Sponsor
Imperial College London
Who can join
Adults 0 Hours to 6 Hours, any sex, with Neonatal Encephalopathy or Asphyxia Neonatorum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will find out if analysing heartbeat in babies with brain injury, based on standard clinical monitors, can inform treatment decisions and monitor stress levels in real time
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03179553
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neonatal Encephalopathy
Currently open trials in the same condition.
- NCT06747260 — Feasibility and Safety of Intranasally Administered Breast Milk in HIE · EARLY_PHASE1 · recruiting
- NCT05889507 — Cooling in Mild Encephalopathy · Phase 3 · recruiting
- NCT05848271 — Natural History Study of Patients with HPDL Mutations · recruiting
- NCT05610085 — A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures · Phase 2 · recruiting
- NCT04603547 — Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy · active not recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03179553 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03179553.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing